Novo Nordisk reports falling market share and margins; 2026 outlook projects a 5-13% decline in sales and operating profit.
AI-driven CCS hypergrowth, margin expansion and $1B CapEx fueling EPS re-rating; see 2026–2028 EPS targets—read now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results